Key result
High admission NT-proBNP in new-onset acute HFpEF is linked to ~16.6-fold higher 12-month mortality.
Why the study?
Heart failure with preserved ejection fraction has been extensively assessed, but few studies have evaluated the predictive value of NT-proBNP specifically in patients presenting with de novo and acute HFpEF.
Does an admission NT-proBNP level ≥ 2910 pg/mL predict 12-month all-cause mortality and rehospitalisation in patients hospitalized for a first acute episode of new-onset HFpEF?
Cohort (n=91)
No
Does an admission NT-proBNP level ≥ 2910 pg/mL predict 12-month all-cause mortality and rehospitalisation in patients hospitalized for a first acute episode of new-onset HFpEF?
In patients presenting with a first acute episode of de novo HFpEF, an admission NT-proBNP level ≥ 2910 pg/mL identifies a 16-fold higher adjusted risk of 1-year mortality, while values below this threshold confer a 99.3% likelihood of 1-year survival.
Answers are grounded in this paper and cite their sources.
May support mortality risk stratification in new-onset HFpEF; leaves open whether thresholds guide therapy in prospective trials.
Background: Heart failure with preserved ejection fraction (HFpEF) has been assessed extensively, but few studies analysed the predictive value of the NT-proBNP in patients with de novo and acute HFpEF. We sought to identify NT-proBNP at admission as a predictor for all-cause mortality and rehospitalisation at 12 months in patients with new-onset HFpEF. Methods: We analysed 91 patients (73 ± 11 years, 68% females) admitted for de novo and acute HFpEF, using the Cox proportional hazard risk model. Results: An admission NT-proBNP level above the threshold of 2910 pg/mL identified increased all-cause mortality at 12 months (AUC = 0.72, sensitivity = 92%, specificity = 53%, p < 0.001). All-cause mortality adjusted for age, gender, medical history, and medication in the augmented NT-proBNP group was 16-fold higher (p = 0.018), but with no difference in rehospitalisation rates (p = 0.391). The predictors of increased NT-proBNP ≥ 2910 pg/mL were: age (p = 0.016), estimated glomerular filtration rate (p = 0.006), left atrial volume index (p = 0.001), history of atrial fibrillation (p = 0.006), and TAPSE (p = 0.009). Conclusions: NT-proBNP above 2910 pg/mL at admission for de novo and acute HFpEF predicted a 16-fold increased mortality at 12 months, whereas values less than 2910 pg/mL forecast a high likelihood of survival (99.3%) in the next 12 months, and should be considered as a useful prognostic tool, in addition to its utility in diagnosing heart failure.
No takes yet. Share an insight, caveat, or question.
Ghilencea et al. (2022) conducted a cohort in New-onset acute heart failure with preserved ejection fraction (HFpEF) (n=91). Admission NT-proBNP >= 2910 pg/mL vs. Admission NT-proBNP < 2910 pg/mL was evaluated on All-cause mortality at 12 months (HR 16.6, 95% CI 1.6-169, p=0.018). Admission NT-proBNP >= 2910 pg/mL in new-onset acute HFpEF predicted a 16.6-fold higher adjusted risk of 12-month all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: